35
Participants
Start Date
July 1, 2022
Primary Completion Date
April 30, 2027
Study Completion Date
February 28, 2030
SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years
500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients \< 30 kg, and 100 mcg for patients ≥ 30 kg.
SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years
500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients \< 30 kg, and 100 mcg for patients ≥ 30 kg.
SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years
500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients \< 30 kg, and 100 mcg for patients ≥ 30 kg.
Memorial Sloan Kettering, New York
Roswell Park Comprehensive Cancer Center, Buffalo
UPMC Children's Hospital of Pittsburgh, Pittsburgh
Children's National, Washington D.C.
Children's Healthcare of Atlanta, Atlanta
University of Florida, Gainsville
Nationwide Children's Hospital, Columbus
Cincinnati Children's Hospital Medical Center, Cincinnati
Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago
Texas Children's Hospital, Houston
Children's Hospital Colorado, Aurora
Children's Hospital Los Angeles, Los Angeles
Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto
Hospital for Sick Children, Toronto
Roswell Park Cancer Institute
OTHER
National Cancer Institute (NCI)
NIH
American Lebanese Syrian Associated Charities
OTHER
Pediatric Brain Tumor Consortium
NETWORK